Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 August 2025 | Story Onthatile Tikoe and the Centre for Teaching and Learning | Photo Supplied
CTL
From the left: Dr Jenny Glennie (SAIDE), Gugu Khanye (Director: Student Success – UFS), Prof Matete Madiba (Deputy Vice-Chancellor – UWC), Prof Francois Strydom (UFS Siyaphumelela Lead), and Prof Nthabiseng Ogude (Siyaphumelela Institutional Coach) at the 2025 Siyaphumelela Conference. The group played a key role in advancing conversations around student success, collaboration, and innovation in higher education.

The University of the Free State (UFS) is advancing a transformative approach to student success that positions it to become a national leader in enhancing social mobility. This vision was underscored at the 2025 Siyaphumelela Conference, where the university shared details of its groundbreaking collaboration with the National Institute for Student Success (NISS) at Georgia State University (GSU) in the United States.

Prof Francois Strydom, Senior Director: Centre for Teaching and Learning (CTL), explained that the initiative builds on lessons from GSU’s remarkable achievements. “The success of Georgia State University has been truly inspiring,” he said. “The NISS approach, which focuses on using data to dismantle systemic barriers and improve graduation rates, has transformed outcomes for a predominantly low-income and diverse student body. By contextualising this data-driven model for our environment, the UFS is proud to be the first university on the African continent to implement it.”

 

Building on proven success

GSU’s success in eliminating equity gaps in retention and completion among different racial groups was achieved through a redesign of its support structures and processes. Drawing on its own established track record of narrowing equity gaps in success rates, the UFS aims to replicate these outcomes in a way that is tailored to its unique context.

At the conference, the UFS Centre for Teaching and Learning (CTL) launched a new national report on student engagement trends and presented papers on a range of topics. These included innovative strategies for improving performance in high-priority modules, the use of predictive analytics to provide proactive student support, and research into gender differences in academic performance and class attendance in a post-COVID world.

Prof Strydom also led an exploratory panel discussion on strengthening collaboration between universities, business, and philanthropy to drive large-scale student success initiatives. “By facilitating a deeper understanding between philanthropic organisations, businesses, and universities, we can develop innovative and impactful approaches to funding and student support,” he said.

 

Driving innovation and sustainability

The UFS’ contributions at the conference were further reinforced by institutional projects focused on the evidence-based integration of artificial intelligence (AI) into student learning and success. These initiatives reflect a clear commitment to transformation that is both research-led and data-driven.

Looking ahead, Prof Strydom emphasised the opportunity before the institution: “We have a unique opportunity to leverage the lessons learnt from our student success initiatives to guide further research, deploy technology in ways that optimise human connection, and help create responsible societal futures while contributing to the sustainability of our university.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept